Drug Development

Blog Post

Clinical Trial Alert: ReveraGen BioPharma Seeks Participants for a Phase 2b DMD Study

By MDA Staff | March 12, 2019
Blog Post

FDA Grants Breakthrough Therapy Designation to Amicus’ Experimental Therapy, AT-GAA, for Late-Onset Pompe Disease

By Jeanene Swanson | March 7, 2019
Blog Post

Clinical Trial Alert: Amicus Therapeutics Seeks Participants for a Phase 3 Late-Onset Pompe Disease Study

By MDA Staff | March 5, 2019
Blog Post

CMTA and MDA Co-Fund Proof-of-Concept Study Using AAV Vector to Deliver Gene Replacement Therapy in X-linked Charcot-Marie-Tooth Disease

By Jeanene Swanson | March 1, 2019
Blog Post

FDA Accepts Sarepta Therapeutics’ New Drug Application (NDA) for Golodirsen to Treat DMD Amenable to Exon 53 Skipping

By Jeanene Swanson | March 1, 2019
Blog Post

Solid Biosciences Announces Preliminary Results of DMD Gene Therapy Trial

By Jeanene Swanson | February 8, 2019
MDA logo
Blog Post

Catalyst Pharmaceuticals Announces Positive Results from Phase 2b Trial of Firdapse in Patients with Muscle-Specific Kinase Antibody Positive Myasthenia Gravis (MuSK-MG)

By Jeanene Swanson | January 30, 2019
clinical-trial-alert-image
Blog Post

Clinical Trial Alert: Brainstorm Cell Therapeutics Seeks Participants for a Phase 3 ALS Study

By MDA Staff | January 16, 2019
MDA logo
Blog Post

FDA Awards Fast Track Status to RNS60, Revalesio’s Investigational Therapy for ALS

By Jeanene Swanson | January 16, 2019
clinical-trial-alert-image
Blog Post

Clinical Trial Alert: Orphazyme Seeks Participants for a Phase 3 ALS Study

By MDA Staff | January 11, 2019